Hyderabad, Telangana, India, November 2025 – Cohance Lifesciences Limited, a leading integrated global CDMO platform, has announced the appointment of Ravinath Shetty as Platform Chief Operating Officer (COO). With a distinguished career spanning nearly 35 years in the pharmaceutical manufacturing and operations domain, Ravinath brings extensive expertise in operations leadership, strategic execution, and site management across some of India’s most reputed pharma organizations.
In his new role, Ravinath will be responsible for strengthening operational excellence, driving value creation, and ensuring cross-functional efficiency across Cohance’s manufacturing and development ecosystem. His appointment underscores Cohance Lifesciences’ commitment to operational agility, scalability, and sustainable growth as it continues to expand its global footprint.
Before joining Cohance Lifesciences, Ravinath Shetty served as President at Apitoria Pharma Private Limited, where he led strategic operations and business excellence initiatives to strengthen the company’s manufacturing capabilities and growth trajectory.
Earlier, Ravinath spent nearly five years at Aurobindo Pharma Ltd, where he rose to the position of Associate President. During his tenure, he was responsible for operational control, regulatory compliance, financial management, and quality systems, playing a key role in driving continuous improvement and strategic alignment across production sites.
Prior to that, Ravinath served as Senior Director of Operations at Dr. Reddy’s Laboratories, where he led large-scale API operations and implemented process improvements to enhance productivity and compliance standards. His leadership at Cipla as Senior Director of Operations and Site Head of API plants further strengthened his expertise in Lean Six Sigma, GMP, and operational excellence.
His earlier career included senior operational leadership roles at Zydus Cadila, Watson Pharmaceuticals, and Lupin Limited, where he spent over 17 years. Across these organizations, Ravinath successfully drove transformation initiatives, optimized manufacturing networks, and fostered high-performing operational cultures.
Ravinath holds an Executive MBA in Strategic Management and Corporate Strategy from the Indian Institute of Management, Kozhikode (IIM-K), and a Bachelor’s degree in Chemical Engineering from the Siddaganga Institute of Technology (SIT), Tumkur. His academic background in engineering and management has equipped him with a strong foundation for integrating technology and strategy into large-scale operational excellence.
About Cohance Lifesciences
Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) is an integrated, technology-driven global CDMO platform committed to advancing therapeutics for a healthier world. The company’s rebranding from Suven Pharma to Cohance marks a bold evolution toward a broader vision rooted in collaboration and innovation.
The name “Cohance” encapsulates its mission — to Collaborate with global innovators and Enhance their molecules, helping bring transformative therapies to patients and consumers worldwide. Through its state-of-the-art manufacturing facilities and strong scientific capabilities, Cohance Lifesciences continues to accelerate innovation in the life sciences ecosystem.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
